Invenomic Capital Management’s Concentrix CNXC Stock Holding History

Invenomic Capital Management’s Portfolio CNXC Stock Details CNXC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-874,241	Closed	-$36.4M	–	157
2025 Q4	$36.4M	Buy	874,241 +51,896	+6%	+$2.11M	1.69%	16
2025 Q3	$38M	Buy	822,345 +135,429	+20%	+$7.22M	1.84%	11
2025 Q2	$36.3M	Buy	686,916 +152,652	+29%	+$8.06M	2.06%	7
2025 Q1	$29.7M	Sell	534,264 -132,169	-20%	-$6.33M	1.5%	16
2024 Q4	$28.8M	Buy	666,433 +194,190	+41%	+$8.64M	1.37%	14
2024 Q3	$24.2M	Buy	472,243 +368,295	+354%	+$24.7M	1.33%	23
2024 Q2	$6.58M	Buy	+103,948	New	+$6.24M	0.32%	91
2023 Q4	–	Sell	-53,528	Closed	-$4.29M	–	181
2023 Q3	$4.29M	Buy	53,528 +29,745	+125%	+$2.33M	0.18%	102
2023 Q2	$1.92M	Buy	+23,783	New	+$2.22M	0.1%	118

Other funds holding CNXC

GBL

Groupe Bruxelles Lambert Brussels, Belgium $62.2M AUM 57.6% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invenomic Capital Management's CNXC Position: Q1 2026 in Review

Invenomic Capital Management sold out of Concentrix (CNXC) in Q1 2026, closing a stake of 874,241 shares — an estimated $36.4M sold.

Invenomic Capital Management first reported a position in CNXC in Q2 2023 and held it in 9 quarters. The position peaked at $38M in Q3 2025. 304 funds tracked by Wall St. Rank hold CNXC as of Q1 2026.

Invenomic Capital Management reported no remaining Concentrix position as of Q1 2026 after selling out during the quarter.
Invenomic Capital Management sold 874,241 Concentrix shares in Q1 2026, an estimated $36.4M.
Invenomic Capital Management first reported a position in Concentrix in Q2 2023 and held it in 9 quarters.
Invenomic Capital Management's Concentrix position peaked at $38M in Q3 2025.
304 funds tracked by Wall St. Rank held Concentrix as of Q1 2026.

Based on Invenomic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.